CORDIS · 848146 · H2020
TO_AITION A high-dimensional approach for unwinding immune-metabolic causes of cardiovascular disease-depression multimorbidities
Coordinator: IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON (EL)
Depression is a common and serious comorbidity of cardiovascular disease (CVD) affecting one in three patients, among which women earlier and more frequently. Depression increases the risk for CVD development, acute events and mortality by >2 fold, independently of traditional risk factors, and constitutes an enormous socioeconomic burden in terms of morbidity, mortality and healthcare costs. Still, the patients at risk, disease trajectories and causative mechanisms involved remain unknown.TO_AITION addresses the hypothesis that immune-metabolic dysregulation, occurring as a result of genetic…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €6.0M awarded to the consortium. The project runs over approximately 6 years from 2020-01-01 to 2025-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from EL
see all →- Theseus — A First of a kind Hub for circularity demonstrator for Attica and peripheral regions101178059 · HORIZON · €20.0M
- COMFORTAGE — Prediction, Monitoring and Personalized Recommendations for Prevention and Relief of Dementia and Frailty101137301 · HORIZON · €17.6M
- Flex2Energy — Automated Manufacturing Production Line for Integrated Printed Organic Photovoltaics101096803 · HORIZON · €15.7M
- HERON — HERON Center of Excellence in Robotics101136568 · HORIZON · €15.0M
- SEAMLESS — Safe, Efficient and Autonomous: Multimodal Library of European Shortsea and inland Solutions101096923 · HORIZON · €15.0M
- FIDAL — Field Trials beyond 5G101096146 · HORIZON · €15.0M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.0M toward a total project budget of €6.0M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-SC1-BHC-2018-2020.
- Who coordinates the project?
- The project is coordinated by IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON (EL).
- What is the project timeline?
- The project runs from 2020-01-01 to 2025-12-31 — approximately 6 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 848146.